Top Searches
Advertisement

Pills, Power, Partnership—Emcure-Sanofi Pact Targets India’s Diabetes Divide


Updated: July 16, 2025 18:15

Image Source : MediCircle
Emcure Pharmaceuticals Ltd and Sanofi India Ltd have announced an exclusive distribution and promotion agreement for Sanofi’s oral anti-diabetic (OAD) drugs in India. The partnership aims to enhance nationwide access to trusted diabetes therapies, effective immediately.
 
Key Highlights:
 
- Emcure will distribute and promote Sanofi’s leading OAD brands, including Amaryl and Cetapin

- Sanofi retains ownership and manufacturing responsibilities for the products

- The collaboration leverages Emcure’s deep distribution network across urban and rural India
 
Market Context:

- Over 100 million Indians live with type 2 diabetes, with more than 60% having uncontrolled blood sugar levels

- The alliance is expected to improve patient outcomes by expanding reach to underserved regions

- No employee transfers will occur between the companies as part of this deal
 
Leadership Commentary:

- Sanofi emphasized unlocking the full potential of its OAD portfolio

- Emcure highlighted the synergy with its existing diabetes care offerings
 
Sources: Business Upturn, Economic Times, Sanofi India Press Releases.

Advertisement

STORIES YOU MAY LIKE

Advertisement

Advertisement